Nonmelanoma Skin Cancer and Cutaneous Viral Diseases: An Update
A supplement to Family Practice News and Internal Medicine News and supported by an unrestricted educational grant from Graceway Pharmaceuticals, LLC. This supplement was jointly sponsored by the Elsevier Office of Continuing Medical Education (EOCME) and Family Practice News and Internal Medicine News.
The articles in this supplement are based on faculty presentations given at a satellite symposium during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, held March 3-9, 2007, in Maui, Hawaii.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 12.
Topics
• Cutaneous Cancer: Combination Treatment Strategies
• Cutaneous Oncology and Immunomodulator Therapy: From Warts to Skin Cancers
• Molluscum Contagiosum: An Evidence-Based Review
Faculty
James M. Spencer, MD, MS
Professor of Clinical Dermatology
Department of Dermatology
Mount Sinai School of Medicine
New York Dr. Spencer is on the speaker's bureau of Graceway. He discusses the off-label/investigational use of imiquimod 5% cream.
James Q. Del Rosso, DO
Clinical Associate Professor, Dermatology
University of Nevada School of Medicine
Touro University
College of Osteopathic Medicine
Dermatology Residency Director
Valley Hospital Medical Center
Las Vegas, Nev. Dr. Del Rosso has received grant support from Allergan Inc., Amgen Inc., Connetics Corporation, Coria Laboratories Ltd., Doak Dermatologics, Galderma Laboratories, L.P., Graceway Pharmaceuticals, LLC, Medicis Pharmaceuticals Corporation, OrthoNeutrogena, Stiefel Laboratories, Inc., and Warner Chilcott. He is a consultant and on the speaker's bureau of Coria, Doak, Galderma, Graceway, Intendis, OrthoNeutrogena, and Stiefel; his is a consultant to Novartis Pharmaceuticals Corporation and Astellas Pharma Inc. Dr. Del Rosso discusses the off-label/investigational uses of imiquimod, 5-fluorouracil, diclofenac, and interferon.
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh Dr. Kress is a consultant to and on the speaker's bureau of Amgen, Connetics, Galderma, Graceway, Novartis, PharmaDerm, and Stiefel.
Target Audience
This activity has been developed for dermatologists and other health care providers who diagnose and treat patients with nonmelanoma skin cancers, molluscum contagiosum, and warts.
Educational Needs
Research focusing on the functioning of the immune system at the molecular level continues to provide support for ongoing work in the further development of immune-modifying agents. Among these are biologic agents that block tumor necrosis factor in diseases such as rheumatoid arthritis and psoriasis, as well as immune response modifiers such as systemic interferons and topical imiquimod. This last agent has been approved for the treatment of several cutaneous diseases and is being studied worldwide for its potential applications in a number of others. Dermatologists need to remain up-to-date as the results of both basic research and clinical studies are published. This supplement provides current information about immunomodulators in several viral and malignant skin diseases.
Learning Objectives
By reading and studying this supplement, participants should be able to:
• Name at least three types of immunomodulators and explain the basic mechanisms by which they work to treat diseases.
• Describe the results of studies demonstrating the benefits of immunomodulator therapy in the treatment of nonmelanoma skin cancers and cutaneous viral diseases.
• Discuss the emerging role of topical medical therapy in the treatment of nonmelanoma skin cancers.
• List and describe the treatment options available for molluscum contagiosum.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Elsevier Office of Continuing Medical Education (EOCME) and Family Practice News and Internal Medicine News. The EOCME is accredited by the ACCME to provide continuing medical education for physicians.
The EOCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
